Podium to Practice: Chicago 2026 – LUNG: HARMONi-6 trial
OR
Studies / Trials Discussed
LBA4 – Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
LBA4 – Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.